Cullinan Therapeutics, Inc. CGEM
As ofNov 17, 2026, 2:25 PM EST
- YTD
- -16.86%
- 1 year
- -1.88%
CGEM free cash flow history
Free cash flow is operating cash flow minus capital expenditure outflow. It can be negative; it is not the same as earnings.
-175,799,000 USD
FY 2025 · Period ended
Coverage: complete. Values in USD; not inflation adjusted.
Reporting currency is USD by the source’s USD conversion factor of 1; the source does not name the currency.
Capital expenditure here is net of asset disposals, so free cash flow can be higher than a figure that subtracts gross purchases.
Scroll the table to see all values →
| Fiscal period | Period end | Free cash flow | YoY change | YoY % |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | -175,799,000 | -30,496,000 | Not meaningful |
| FY 2024 | 2024-12-31 | -145,303,000 | -10,820,000 | Not meaningful |
| FY 2023 | 2023-12-31 | -134,483,000 | -6,777,000 | Not meaningful |
| FY 2022 | 2022-12-31 | -127,706,000 | -84,273,000 | Not meaningful |
| FY 2021 | 2021-12-31 | -43,433,000 | -13,651,000 | Not meaningful |
| FY 2020 | 2020-12-31 | -29,782,000 | -8,865,000 | Not meaningful |
| FY 2019 | 2019-12-31 | -20,917,000 | -7,107,000 | Not meaningful |
| FY 2018 | 2018-12-31 | -13,810,000 | Not available | Not available |
Percentage growth is shown only when the same fiscal period one year earlier has a positive value. Missing periods are not estimated.
Company-reported financial statements. Retrieved 2026-05-22T14:43:12.000Z. Retrieval time is not a report date.
Open full statementsUse Add to watchlist above to save this stock.
